Atossa Therapeutics (ATOS) announced that the U.S. FDA issued a “Study May Proceed” letter for the company’s study in metastatic breast cancer which was the subject of a recent investigational new drug application for (Z)-endoxifen. “This letter marks an important regulatory milestone for Atossa and to potentially expand the use of (Z)-endoxifen for metastatic ER+/HER2- Breast Cancer. We believe its activity, even in tumors that have developed resistance to other endocrine therapies and in the oncogenic signaling pathway, protein kinase C beta 1, may offer a new tool in treating this disease.,” said Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics President and CEO. “We appreciate the FDA’s review and look forward to advancing this clinical investigation.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential
- Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics
- Atossa Therapeutics presents four trial updates on Z-endoxifen
- Atossa Therapeutics receives FDA RPD designation to (Z)-Endoxifen
- Atossa Therapeutics issued U.S. patent covering endoxifen formulations